AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16269401 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative treatment
Number of subjects: 14
Study 14675849 — intervention group
Group type: EXPERIMENTAL
Intervention: New drug treatment
Number of subjects: 0
Study 10520100 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous patient‐controlled analgesia (PCA) (bolus dose 2.5 mg diamorphine in 1 ml with a 20‐minute lockout)
Number of subjects: 100
Study 10520100 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient‐controlled analgesia (PCA) (bolus dose 0.5 mg diamorphine in 1 ml with a 5‐minute lockout)
Number of subjects: 100
Study 7743764 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 85
Study 7743764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 1963127 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical method A for reattaching the retina
Number of subjects: 0
Study 1963127 — intervention group
Group type: COMPARATOR
Intervention: Surgical method B for reattaching the retina
Number of subjects: 0
Study 7212331 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O:O2 combined with fentanyl (n = 20)
Number of subjects: 67
Study 7212331 — intervention group
Group type: EXPERIMENTAL
Intervention: enflurane (n = 24)
Number of subjects: 67
Study 7212331 — intervention group
Group type: EXPERIMENTAL
Intervention: halothane (n = 23)
Number of subjects: 67
Study 29623407 — intervention group
Group type: COMPARATOR
Intervention: HOT (33 °C, 8-h sleep opportunity)
Number of subjects: 31
Study 29623407 — intervention group
Group type: EXPERIMENTAL
Intervention: HOT+SR (33 °C, 4-h sleep opportunity)
Number of subjects: 31
Study 27102200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 25
Study 27102200 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 25
Study 27102200 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP19A1 polymorphisms
Number of subjects: 25
Study 24559097 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised pre-performance routines (PPRs)
Number of subjects: 20
Study 24559097 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study 23248037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB) add-on therapy
Number of subjects: 25
Study 18845036 — intervention group
Group type: EXPERIMENTAL
Intervention: Type one tympanoplasty along with cortical mastoidectomy
Number of subjects: 68
Study 18845036 — intervention group
Group type: COMPARATOR
Intervention: Type one tympanoplasty alone
Number of subjects: 68
Study 18087553 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10.0 mg/d
Number of subjects: 480
Study 18087553 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10.0 mg + Folic acid 0.4 mg/d
Number of subjects: 480
Study 18087553 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10.0 mg + Folic acid 0.8 mg/d
Number of subjects: 480
Study 15824681 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (HDE) 0.1 mg/kg for initial dose and 0.2 mg/kg for subsequent doses
Number of subjects: 230
Study 15824681 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (HDE)
Number of subjects: 230
Study 15824681 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose epinephrine (SDE) 0.01 mg/kg
Number of subjects: 230
Study 15824681 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose epinephrine (SDE)
Number of subjects: 230
Study 12473877 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 9014
Study 12473877 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 9014
Study 9830877 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support intervention
Number of subjects: 363
Study 9830877 — intervention group
Group type: EXPERIMENTAL
Intervention: Education about appropriate use of the health care system
Number of subjects: 363
Study 9830877 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of social support and education
Number of subjects: 363
Study 9830877 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 363
Study 7990367 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave resonance treatment (MRT)
Number of subjects: 0
Study 2660322 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcuticular resorbable suture
Number of subjects: 166
Study 2660322 — intervention group
Group type: COMPARATOR
Intervention: Monofilament nylon mattress suture
Number of subjects: 166
Study 28252881 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 40
Study 28252881 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 40
Study 27641426 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediolateral episiotomy
Number of subjects: 666
Study 27641426 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral episiotomy
Number of subjects: 666
Study 23952289 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg)
Number of subjects: 190
Study 23952289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 23027399 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast dynamic stretching (FDS) of the gluteus maximus muscle
Number of subjects: 12
Study 20453574 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding education and support services
Number of subjects: 39
Study 20453574 — intervention group
Group type: COMPARATOR
Intervention: Breast-feeding education only (control group)
Number of subjects: 39
Study 20078015 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth system during episode of care
Number of subjects: 0
Study 20078015 — intervention group
Group type: COMPARATOR
Intervention: Routine home visits only
Number of subjects: 0
Study 16160626 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (PAR) up to 40 mg daily
Number of subjects: 49
Study 16160626 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (VEN-XR) up to 225 mg daily
Number of subjects: 49
Study 16160626 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study 14672467 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral training for urge incontinence (8 weeks, four visits)
Number of subjects: 258
Study 14672467 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral training for stress incontinence (8 weeks, four visits)
Number of subjects: 258
Study 10539493 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 10539493 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 8857627 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient programme (4 weeks)
Number of subjects: 121
Study 8857627 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient programme (8 half days per week)
Number of subjects: 121
Study 8857627 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 121
Study 8314541 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 35
Study 8314541 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy and radiotherapy
Number of subjects: 35
Study 3303886 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg every 6 hours)
Number of subjects: 576
Study 3303886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 3303886 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 576
Study 31558624 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg daily oral sustained-release morphine
Number of subjects: 284
Study 31558624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 29995672 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 42
Study 29995672 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine H2 receptor blockers (H2RBs)
Number of subjects: 42
Study 29995672 — intervention group
Group type: COMPARATOR
Intervention: No coadministration of gastric acid suppressants (Control group)
Number of subjects: 42
Study 28025956 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory nutrition promotion (CPNP) programme
Number of subjects: 1790
Study 28025956 — intervention group
Group type: COMPARATOR
Intervention: Control group (government nutrition programme only)
Number of subjects: 1790
Study 25867913 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF (Tenofovir Alafenamide)
Number of subjects: 153
Study 25867913 — intervention group
Group type: COMPARATOR
Intervention: Darunavir + cobicistat + emtricitabine/tenofovir disoproxil fumarate (TDF)
Number of subjects: 153
Study 23632800 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocar‐guided transvaginal mesh insertion
Number of subjects: 79
Study 23632800 — intervention group
Group type: COMPARATOR
Intervention: Anterior colporrhaphy
Number of subjects: 79
Study 23632800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (mesh and colporrhaphy)
Number of subjects: 79
Study 21763057 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie
Number of subjects: 66
Study 21763057 — intervention group
Group type: EXPERIMENTAL
Intervention: Stylet
Number of subjects: 66
Study 21763057 — intervention group
Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope
Number of subjects: 66
Study 21763057 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq™
Number of subjects: 66
Study 21763057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask (ILMA)
Number of subjects: 66
Study 21763057 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intubation
Number of subjects: 66
Study 19576015 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF(165) cultured dendritic cells in vitro
Number of subjects: 81
Study 19576015 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum VEGF in OSCC patients
Number of subjects: 81
Study 19576015 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood DC in OSCC patients
Number of subjects: 81
Study 19576015 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of VEGF in primary foci
Number of subjects: 81
Study 16784647 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 39
Study 16784647 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial bypass
Number of subjects: 39
Study 15109930 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking (SM)
Number of subjects: 24
Study 15109930 — intervention group
Group type: COMPARATOR
Intervention: Non‐smoking (NS)
Number of subjects: 24
Study 11684139 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep phase advance (SPA) after total sleep deprivation (TSD)
Number of subjects: 30
Study 11684139 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 30
Study 11684139 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (TSD)
Number of subjects: 30
Study 8921561 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-propanol exposure
Number of subjects: 23
Study 8921561 — intervention group
Group type: COMPARATOR
Intervention: Room air exposure
Number of subjects: 23
Study 8921561 — intervention group
Group type: EXPERIMENTAL
Intervention: CSERP measurements
Number of subjects: 23
Study 8921561 — intervention group
Group type: EXPERIMENTAL
Intervention: General challenge response
Number of subjects: 23
Study 1748229 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (150 mg/day)
Number of subjects: 0
Study 1748229 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + dipyridamole (225 mg/day)
Number of subjects: 0
Study 1748229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6847332 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus supportive-expressive psychotherapy
Number of subjects: 110
Study 6847332 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus cognitive-behavioral psychotherapy
Number of subjects: 110
Study 6847332 — intervention group
Group type: COMPARATOR
Intervention: Drug counseling alone
Number of subjects: 110
Study 30205936 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day
Number of subjects: 244
Study 30205936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 27571390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined minimal footwear transition and gait-retraining
Number of subjects: 24
Study 27571390 — intervention group
Group type: COMPARATOR
Intervention: Gait-retraining only (Control)
Number of subjects: 24
Study 25822519 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory, Tactile, Visual, and Vestibular (ATVV) intervention
Number of subjects: 183
Study 23464577 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin desensitization (100 mg daily)
Number of subjects: 70
Study 21406089 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative investigation of recruitment strategies and trial design changes implemented in Phase II.
Number of subjects: 0
Study 21406089 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes to study information and recruitment strategies implemented in Phase II.
Number of subjects: 0
Study 21406089 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative investigation findings and implemented changes.
Number of subjects: 0
Study 18976766 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg daily for 12 months)
Number of subjects: 53
Study 18976766 — intervention group
Group type: COMPARATOR
Intervention: Control (no drugs for 12 months)
Number of subjects: 53
Study 17194546 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/A (Botox)
Number of subjects: 18
Study 17194546 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (NS)
Number of subjects: 18
Study 15152709 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 80
Study 15152709 — intervention group
Group type: COMPARATOR
Intervention: Peer Group Therapy
Number of subjects: 80
Study 11223729 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methacholine
Number of subjects: 19
Study 11223729 — intervention group
Group type: COMPARATOR
Intervention: BHR(+) group (12 patients with bronchial hyperresponsiveness)
Number of subjects: 19
Study 9326704 — intervention group
Group type: EXPERIMENTAL
Intervention: Vomer flap with a skin graft (VF group)
Number of subjects: 12
Study 9326704 — intervention group
Group type: COMPARATOR
Intervention: Mucoperiosteal pushback procedure (PB group)
Number of subjects: 12
Study 7942049 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (400 I.U. d‐1) and ascorbic acid (200 mg d‐1) supplementation
Number of subjects: 24
Study 7942049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3263876 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg daily
Number of subjects: 0
Study 3263876 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60-80 mg daily
Number of subjects: 0
Study 3263876 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 100 mg daily
Number of subjects: 0
Study 3263876 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 150-200 mg daily
Number of subjects: 0
Study 4571680 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleate supplementation
Number of subjects: 75
Study 4571680 — intervention group
Group type: COMPARATOR
Intervention: Oleate mixture
Number of subjects: 75
Study 31797437 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision, carbon dioxide (CO2) laser therapy, and triamcinolone acetonide (TAC) intralesional injections during surgery and follow-up.
Number of subjects: 21
Study 29353534 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD) challenge
Number of subjects: 35
Study 29353534 — intervention group
Group type: COMPARATOR
Intervention: TRP‐balanced control condition (BAL)
Number of subjects: 35
Study 28637744 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based care model
Number of subjects: 0
Study 28637744 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 0
Study 25592133 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN + ELD
Number of subjects: 219
Study 25592133 — intervention group
Group type: COMPARATOR
Intervention: ALN + VitD
Number of subjects: 219
Study 22925277 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum sterilisation with titanium clip
Number of subjects: 0
Study 22925277 — intervention group
Group type: COMPARATOR
Intervention: Partial salpingectomy
Number of subjects: 0
Study 21486976 — intervention group
Group type: COMPARATOR
Intervention: IM20 × 3 (standard dose, 20 μg)
Number of subjects: 437
Study 21486976 — intervention group
Group type: EXPERIMENTAL
Intervention: IM40 × 4 (double doses, 40 μg)
Number of subjects: 437
Study 21486976 — intervention group
Group type: EXPERIMENTAL
Intervention: ID4 × 4 (low doses, 4 μg)
Number of subjects: 437
Study 18392831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultravist 300 (300 mg iodine/ml) at a flow rate of 4.9 ml/s, 148 ml
Number of subjects: 192
Study 18392831 — intervention group
Group type: COMPARATOR
Intervention: Ultravist 370 (370 mg iodine/ml) at a flow rate of 4.0 ml/s, 120 ml
Number of subjects: 192
Study 16870002 — intervention group
Group type: EXPERIMENTAL
Intervention: High in non‐dairy Ca (calcium citrate) but low in vitamin D (HC)
Number of subjects: 8
Study 16870002 — intervention group
Group type: EXPERIMENTAL
Intervention: High in dairy Ca and vitamin D (HD)
Number of subjects: 8
Study 16870002 — intervention group
Group type: COMPARATOR
Intervention: Low in dairy Ca and vitamin D (LD; control)
Number of subjects: 8
Study 16870002 — intervention group
Group type: EXPERIMENTAL
Intervention: All sources of Ca intake
Number of subjects: 8
Study 12931764 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush A (Sonicare Plus) activated
Number of subjects: 0
Study 12931764 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush B (Braun Oral B) activated
Number of subjects: 0
Study 10873733 — intervention group
Group type: EXPERIMENTAL
Intervention: Early elective surgery
Number of subjects: 1090
Study 10873733 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography surveillance until aneurysm diameter exceeded 5.5 cm
Number of subjects: 1090
Study 10873733 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without any trace of plasma cotinine
Number of subjects: 1090
Study 10873733 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 1090
Study 10873733 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV(1) levels
Number of subjects: 1090
Study 10873733 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive for plasma cotinine
Number of subjects: 1090
Study 10873733 — intervention group
Group type: EXPERIMENTAL
Intervention: Without trace of plasma cotinine
Number of subjects: 1090
Study 9069163 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of lumbar bone mineral density and routine biochemical parameters (serum phosphorus, estrone, androstenedione, and urine calcium)
Number of subjects: 92
Study 9069163 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminant functions based on lumbar bone density and biochemical parameters
Number of subjects: 92
Study 8511445 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled vaccine
Number of subjects: 0
Study 8511445 — intervention group
Group type: EXPERIMENTAL
Intervention: Log method
Number of subjects: 0
Study 8511445 — intervention group
Group type: EXPERIMENTAL
Intervention: Score method
Number of subjects: 0
Study 8511445 — intervention group
Group type: EXPERIMENTAL
Intervention: Poisson method
Number of subjects: 0
Study 2980547 — intervention group
Group type: EXPERIMENTAL
Intervention: Iotrolan
Number of subjects: 0
Study 2980547 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 0
Study 2980547 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 0
Study 29860224 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca block (FIB)
Number of subjects: 50
Study 29860224 — intervention group
Group type: COMPARATOR
Intervention: Lumbar plexus block (LPB)
Number of subjects: 50
Study 27321165 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 (sacubitril/valsartan)
Number of subjects: 26
Study 27321165 — intervention group
Group type: COMPARATOR
Intervention: simvastatin
Number of subjects: 26
Study 24801467 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 42
Study 24801467 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 22595386 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (4 g daily for 8 weeks)
Number of subjects: 17
Study 20517959 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus eluting stent (EES)
Number of subjects: 60
Study 20517959 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (control)
Number of subjects: 60
Study 18035098 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 160 mg daily for 26 weeks
Number of subjects: 237
Study 18035098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 16186437 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with aspirin
Number of subjects: 120
Study 16186437 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus colchicine 1.0 to 2.0 mg for the first day and then 0.5 to 1.0 mg/d for 3 months
Number of subjects: 120
Study 12375656 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets stored for 5 days
Number of subjects: 24
Study 12375656 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets stored for 7 days
Number of subjects: 24
Study 11715489 — intervention group
Group type: EXPERIMENTAL
Intervention: GLN group (glutamine dipeptide enriched enteral nutrition at 0.5 g.kg‐1.day‐1)
Number of subjects: 24
Study 11715489 — intervention group
Group type: EXPERIMENTAL
Intervention: GLN group
Number of subjects: 24
Study 8637957 — intervention group
Group type: EXPERIMENTAL
Intervention: Taiwan Aboriginal Acculturation Scale (TAAS)
Number of subjects: 144
Study 2316233 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide gel (30 mL) with quinidine gluconate (648 mg)
Number of subjects: 8